EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
Liver Cancer Summit 202320-22 April, Estoril
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| 1-P08 | Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for hepatocellular carcinoma in type 2 diabetes mellitus: A population-based study | Huang Helen |  Received |
 |
|||
| 1-P11 | Tumour associated endothelial expression of B7-H3 predicts survival in hepatocellular carcinomas | Su Jong Yu | Received |
|
|||
| 1-P10 | CT texture analysis may predict genetic profile of mass-forming intrahepatic cholangiocarcinoma | Lorenza Rimassa | Received |
|
|||
| 1-P06 | A Notch-ligand producing niche drives the transition of pre-malignant biliary disease into cholangiocarcinoma | Anabel Martinez Lyons | Received |
|
|||
| 1-P09 | Implication of patients experience in the liver cancer multidisciplinary approach | Gemma Iserte | Received |
|
|||
| 1-P07 | Efficacy of atezolizumab in combination with bevacizumab in patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy: efficacy results from the interim analysis of the Phase IIIb Italian AMETHISTA trial | Lorenza Rimassa | Received |
|
|||
| 1-P05 | Macrotrabecular-Massive pattern is associated with aggressive factors, but it is not an independent predictor of tumor recurrence and overall survival in patients with hepatocellular carcinoma treated with liver resection. | Alejandro Forner | Received |
|
|||
| 1-P01 | Atezolizumab in combination with bevacizumab in patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy: safety results from the interim analysis of the phase IIIb Italian AMETHISTA trial | Fabio Piscaglia | Received |
|
|||
| 1-P04 | Liquid biopsy protein biomarkers of cholangiocarcinoma risk, early diagnosis and survival mirroring tumor cells | Ainhoa Lapitz | Received |
|
|||
| 1-P03 | Myeloid cell-derived HMGB1 protects from the development of hepatocellular carcinoma | Natalia Nieto | Received |
|
|||
| 1-P02 | A novel hepatitis B virus genome integration hotspot in DEPDC5 intron-10 predicts unfavourable prognosis for hepatocellular carcinoma patients | Chau-Ting Yeh | Received |
|
|||
| 2-P03 | MAP17 promotes an epithelial-mesenchymal-amoeboid transition in hepatocellular carcinoma by switching one-carbon metabolism | Claudia Gil-Pitarch | Received |
|
|||
| 2-P05 | Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction | Claudia Fulgenzi | Received |
|
|||
| 2-P08 | Transarterial chemoembolization and systemic treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma: Outcome and safety profile | Louisa Stern | Received |
|
|||
| 2-P11 | GALAD score outperforms aMAP and ALBI scores in the 5- and 10-year prediction ofhepatocellular carcinoma (HCC) development in patients with compensated advanced chronicliver disease (cACLD): a 12-year prospective study. | Valentina Baldaccini | Received |
|
|||
| 2-P09 | KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor | Pedro Miguel Rodrigues | Received |
|
|||
| 2-P04 | Real World Data for Atezolizumab plus Bevacizumab in unresectable Hepatocellular Carcinoma: how does the adherence to the IMbrave150 trial inclusion criteria impact prognosis? | Margherita Rimini | Received |
|
|||
| 2-P07 | Role of SerpinB3-PD polymorphism in the prognosis of hepatocellular carcinoma | Pietro Guerra | Received |
|
|||
| 2-P01 | Regorafenib in patients with unresectable hepatocellular carcinoma in real-world practice: Final analysis of the prospective, observational REFINE study in the sorafenib-intolerant patient subgroup | Elena Dimitriou | Received |
|
|||
| 2-P06 | Safety and feasibility of Atezolizumab and Bevacizumab downstaging to liver transplantation of intermediate-advanced HCC: preliminary European experience on 7 patients | Sherrie Bhoori | Received |
|
|||
| 2-P02 | Mining the dark proteome to identify novel biomarkers in hepatocellular carcinoma | Doan Duy Hai Tran | Received |
|
|||
| 3-P06 | Immunotherapy resistance in NASH-HCC is driven by the dysfunctional liver microenvironment of NASH | Daniel Geh | Received |
|
|||
| 3-P08 | Effect of Zinc Acexamate treatment in hepatocellular carcinoma in vitro and in vivo models | Monica Higuera | Received |
|
|||
| 3-P04 | Exportin-1 (XPO-1) as a novel target for natural killer cells in hepatocellular carcinoma | Salim Khakoo | Received |
|
|||
| 3-P09 | Comparison between Regular Additional Endobiliary Radiofrequency Ablation and Photodynamic Therapy in Patients with Advanced Extrahepatic Cholangiocarcinoma under Systemic Chemotherapy | Christian Möhring | Received |
|
|||
| 3-P03 | Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring lipid metabolism | Mikel Ruiz de Gauna | Received |
|
|||
| 3-P07 | Identification of hepatocyte-restricted antigens, epitopes, and T cell receptors to treat recurrent hepatocellular carcinoma after liver transplantation | Yannick Rakké | Received |
|
|||
| 3-P10 | Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments | Mara Persano | Received |
|
|||
| 3-P11 | Incidence and risk factors of esophagogastric varices bleeding in patients with advanced Hepatocellular Carcinoma treated with Lenvatinib | Eleonora Alimenti | Received |
|
|||
| 3-P05 | Interplay between genetic and immune factors in the tumor microenvironment and their prognostic value in hepatocellular carcinoma. | Filip Ambrozkiewicz | Received |
|
|||
| 3-P02 | Management of varices but not anticoagulation is associated with improved outcome in patients with hepatocellular carcinoma and macrovascular tumour invasion | Lorenz Balcar | Received |
|
|||
| 3-P01 | Glypican-3 targeted radiopharmaceutical therapy for hepatocellular carcinoma: Preclinical characterization of a novel peptide binder | Gary Li | Received |
|
|||
| 4-P11 | Time-trends in cholangiocarcinoma incidence - a Danish nationwide cohort study | Morten Daniel Jensen | Received |
|
|||
| 4-P04 | Artificial intelligence and deep learning models used for the classification and navigation of liver ultrasound protocols for patients with hepatocellular carcinoma | Joseph Klepich | Received |
|
|||
| 4-P01 | Barriers to hepatocellular carcinoma screening at a single Veterans Affairs center: a quality improvement initiative | Maureen Onweni-Eze | Received |
|
|||
| 4-P03 | The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab. | Antonio DAlessio | Received |
|
|||
| 4-P02 | Value based Healthcare: Patient perception of the liver cancer Advanced Practice Nurse care at the Barcelona Clinic Liver Cancer | Neus Llarch | Received |
|
|||
| 4-P06 | Peripheral immune markers can detect hepatocellular carcinoma in blood in a Latin American cohort | Boonstra Andre | Received |
|
|||
| 4-P05 | Cryptogenic non-cirrhotic HCC: clinical, prognostic and immunologic aspects of an emerging HCC etiology | Boonstra Andre | Received |
|
|||
| 4-P09 | Dissecting the tumor heterogeneity and tumor microenvironment in intrahepatic cholangiocarcinoma using spatial transcriptomics | Mareike Polenkowski | Received |
|
|||
| 4-P10 | An innovative human-derived Cholangiocarcinoma-on-chip as a platform for targeted therapy | Michela Anna Polidoro | Received |
|
|||
| 4-P08 | The role of Aurora kinase A in hepatocellular carcinoma: possible regulation of Programmed death-ligand 1 | Luca Grisetti | Received |
|
|||
| 4-P07 | Fibroblast growth factor 21 delays hepatocellular carcinoma development and is critical for liver regeneration in a murine model of moderate and severe liver injury | Hanna Luisa Martin | Received |
|
|||
| 5-P01 | Predicting cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib | Bernardo Stefanini | Received |
|
|||
| 5-P11 | Therapeutic potential of targeting protein hyper-SUMOylation in cholangiocarcinoma | Paula Olaizola Rebe | Received |
|
|||
| 5-P07 | The earliest integration of hepatitis B virus into hepatocyte genome: sites, mechanism and role in HCC oncogenesis | Thomas I. Michalak | Received |
|
|||
| 5-P10 | Targeting epigenetics in preclinical models of Hepatocellular Carcinoma for translational therapy. | Anastasia Georgakopoulou | Received |
|
|||
| 5-P08 | A novel hepatocellular cancer patient derived organoid xenograft model to investigate impact of liver regeneration on tumor growth | Fabian Haak | Received |
|
|||
| 5-P03 | Centrosome amplification is attributed to glutamine metabolism in the developments of liver fibrosis and liver tumors | Caroline Oi-Ling Yu | Received |
|
|||
| 5-P06 | Impact of the covid-19 pandemic on the treatment of resectable liver neoplasias: a cross-sectional study from Brazil | Laynara Vitória Da Silva Vieira | Received |
|
|||
| 5-P05 | ASSOCIATION OF TP53 WITH DEFECTIVE LONG CHAIN 3-HYDROXY ACYL-CoA DEHYDROGENASE INDUCED NON-CIRRHOTIC HEPATOCELLULAR CARCINOMA | Tripti Khare | Received |
|
|||
| 5-P09 | Prognostic impact of metastatic site in patients receiving first-line sorafenib therapy for advanced hepatocellular carcinoma | Luca Ielasi | Received |
|
|||
| 6-P05 | Preferential effects of PARP-1 inhibition in KRAS-mutated intrahepatic cholangiocarcinoma is mediated by CHK1 kinase | Darko Castven | Received |
|
|||
| 6-P06 | Gamma-aminobutyric acid B2 receptor as a potential therapeutic target for cholangiocarcinoma with diabetes mellitus | Charupong Saengboonmee | Received |
|
|||
| 6-P02 | Novel platinum-based chemotherapeutic agents halt cholangiocarcinoma progression through the induction of inter-strand DNA breaks, preventing DNA repair mechanisms | Irene Olaizola Rebe | Received |
|
|||
| 6-P07 | KDM2A histone demethylase ablation restores immunogenicity in liver cancer | Elisa Morganti | Received |
|
|||
| 6-P03 | Proteomic profile matching predicts treatment response in advanced hepatocellular carcinoma for precision medecine | Frederic SALTEL | Received |
|
|||
| 6-P10 | Metabolic rewiring by increased mitochondrial respiration drives immunosuppression in liver cancer | Naroa Goikoetxea Usandizaga | Received |
|
|||
| 6-P01 | Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients. | Margherita Rimini | Received |
|
|||
| 6-P08 | A prognostic nomogram of CDKs/CDKLs-related genes for hepatocellular carcinoma | Ningning Zhang | Received |
|
|||
| 6-P04 | Scavenger receptor MARCO is associated with an immunosuppressive microenvironment and tumor progression in intrahepatic cholangiocarcinoma | Aloña Agirre Lizaso | Received |
|
|||
| 7-P02 | Modelling hepatocellular carcinoma in precision-cut liver slices for therapeutic screening and as a precision medicine tool | Amy Collins | Received |
|
|||
| 7-P03 | Identification and experimental validation of druggable epigenetic targets in hepatoblastoma. | Claveria-Cabello Alex | Received |
|
|||
| 7-P10 | T cell and myeloid cell interactions differ in tumour and non-tumour regions in hepatocellular carcinoma | Cositha Santhakumar | Received |
|
|||
| 7-P08 | Baveno VI and VII criteria are not suitable for screening of large size esophageal varices and clinically significant portal hypertension in patients with HCC | Manon Allaire | Received |
|
|||
| 7-P07 | Metformin and statin reduce the risk of hepatocellular carcinoma among chronic hepatitis C patients failed to antiviral therapy | Pei-Chien Tsai | Received |
|
|||
| 7-P06 | Pediatric liver cancer: Hepatoblastoma and Neddylation post-translational modification | Leidy Estefanía Zapata-Pavas | Received |
|
|||
| 7-P05 | Developing image-guided precision radiotherapy in preclinical liver cancer models | Stephanie May | Received |
|
|||
| 7-P09 | Trial in progress: An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab in locally advanced unresectable or metastatic hepatocellular carcinoma | Jane Kovalevich | Received |
|
|||
| 7-P11 | miRNome profiling analysis reveals novel hepatocellular carcinoma diagnostic, prognostic and treatment-related candidate biomarkers: post-hoc analysis of SORAMIC trail | Egidijus Morkunas | Received |
|
|||
| 7-P04 | Portal-hypertension parameters are associated with survival and ascites occurrence in patients with hepatocellular carcinoma treated by external radiotherapy | Héloïse Giudicelli | Received |
|
|||
| 7-P01 | Silencing CNNM4 in cholangiocarcinoma inhibits tumoral progression by means of non-canonical ferroptosis | Maria Mercado-Gómez | Received |
|
|||
| 8-P03 | Spheroids derived from aggressive hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA) share similar behaviour after proangiogenic stimulation | Adriana Romanzi | Received |
|
|||
| 8-P11 | secondary surveillance following curative treatment of hepatocellular carcinoma: a systematic review | Shauntelle Quammie | Received |
|
|||
| 8-P01 | MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma | Ilaria Leoni | Received |
|
|||
| 8-P09 | Oncogenic role of the Hepatitis B Virus surface antigen during hepatocarcinogenesis | Agustiningsih Agustiningsih | Received |
|
|||
| 8-P08 | Impact of sarcopenia on survival of patients with hepatocellular carcinoma treated with sorafenib | Lorenzo Lani | Received |
|
|||
| 8-P07 | The Differences in Profiles of Intratumoral Microbiota in Cholangiocarcinoma and Hepatocellular Carcinoma are Observed | Thanika Ketpueak | Received |
|
|||
| 8-P06 | Clinical and biologic qualification of the ABRS gene signature, a putative biomarker of benefit to atezolizumab and bevacizumab in advanced hepatocellular cancer | Cian Murphy | Received |
|
|||
| 8-P04 | Incidence rates, trends, and survival for etiology-specific hepatocellular carcinoma and cholangiocarcinoma in the Unites States. | Paulo Pinheiro | Received |
|
|||
| 8-P05 | Cytokine levels and circulating DNA profiling in plasma as biomarkers of response to immunotherapy in hepatocellular carcinoma | Elena Vargas Accarino | Received |
|
|||
| 8-P02 | Phenotypic characteristics of primary cholangiocarcinoma in a large French cohort of patients with viral chronic liver disease followed-up before and after viral eradication: an ANRS study | Alina Pascale | Received |
|
|||
| 8-P10 | Collagen proportionate area (CPA) measurement of liver parenchyma and hepatocellular carcinoma (HCC) can predict HCC recurrence after liver resection | Federico Ravaioli | Received |
|
|||
| 9-P10 | Uncovering epigenetic essentialities of intrahepatic cholangiocarcinoma | Juan Lafuente-Barquero | Received |
|
|||
| 9-P07 | Hepatocellular Carcinoma in HIV-infected patients: clinical presentation and outcomes | Eleonora Alimenti | Received |
|
|||
| 9-P06 | Correlation of single nucleotide polymorphisms and hepatocellular carcinoma in a Latin American population | Boonstra Andre | Received |
|
|||
| 9-P08 | Stabilization of O-GlcNAcylation increases Enhancer of Zeste Homolog 2 (Ezh2) direct targets in hepatocellular carcinoma | Margot Thirion | Received |
|
|||
| 9-P02 | chimeric antigen receptor-engineered memory-like natural killer cells: a novel therapy for hepatocellular carcinoma | Rosalba Biondo | Received |
|
|||
| 9-P11 | Landmark analysis of the risk of recurrence after resection or ablation for hepatocellular carcinoma: a nationwide study | Frederik Kraglund | Received |
|
|||
| 9-P01 | Developing new therapies for primary liver cancer with precision bio-printed patient-derived organoids | Benjamin Dwyer | Received |
|
|||
| 9-P09 | Impact of PNPLA3 rs738409 polymorphism on the development of hepatocellular carcinoma in female patients with non-alcoholic fatty liver disease and severe liver fibrosis | Nuria Pérez Diaz del Campo | Received |
|
|||
| 9-P05 | Evaluation of ESPL1 level in peripheral blood of patients with HBV infection for early warning of HCC occurrence and recurrence | Hengkai Liang | Received |
|
|||
| 10-P04 | Predictive performance of HCC risk scores in chronic hepatitis C patients with advanced fibrosis after achieving SVR: Real-world experience from a tertiary UK centre | Riham Soliman | Received |
|
|||
| 10-P10 | Adverse events related to atezolizumab-bevacizumab is comparable among CTP-A and B and more safer than TKIs for Hepatocellular carcinoma | Anand Kulkarni | Received |
|
|||
| 10-P05 | Correction for length bias reduces the mortality benefit from Hepatocellular Carcinoma surveillance | Callum Robins | Received |
|
|||
| 10-P09 | Novel approaches to improve immunotherapy for NASH-induced HCC | Chaofan Fan | Received |
|
|||
| 10-P06 | Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis | Rodolfo Sacco | Received |
|
|||
| 10-P11 | identifying and analyzing metabolic reprogramming in hcc. | Asha Balakrishnan | Received |
|
|||
| 10-P02 | miR-21-5p promotes NASH-related hepatocarcinogenesis | André L. Simão | Received |
|
|||
| 10-P01 | The tumor milieu of Intrahepatic Cholangiocarcinoma: dissecting the phenotypical and molecular properties of B lymphocytes in affected patients | Giulia Milardi | Received |
|
|||
| 10-P07 | Hepatocellular carcinoma (HCC) management in a tertiary HPB centre - lessons from the southeast coast of the UK | Darren DSouza | Received |
|
|||
| 10-P03 | RIPK3 impacts tumor burden and liver immunophenotype in toxic/dietary models of hepatocellular carcinoma | André Cardador | Received |
|
|||
| 11-P02 | The importance of contrast enhanced ultrasonography and elastography as predictors for hepatocellular carcinoma recurrence following treatment with percutaneous microwave ablation or transarterial chemoembolization | Razvan Rababoc | Received |
|
|||
| 11-P07 | Regorafenib in patients with unresectable hepatocellular carcinoma in real-world practice in the European Union: Final analysis of the prospective, observational REFINE study | Elena Dimitriou | Received |
|
|||
| 11-P06 | Prognostic performance of Toronto HCC risk index and the alpha-fetoprotein rate in patients with Hepatocellular carcinoma | Nouha Trad | Received |
|
|||
| 11-P01 | Tolerability of first line systemic therapy in elderly patients with advanced hepatocellular carcinoma | Giulia Francesca Manfredi | Received |
|
|||
| 11-P10 | Alpha-Fetoprotein Response Patterns after Y-90 Radioembolization for Intermediate-to-Advanced Hepatocellular Carcinoma Predict Disease Progression and Survival | Justin Tse | Received |
|
|||
| 11-P05 | The epidemiology of hepatocellular carcinoma has changed in our region ... But, what has really changed ? | Edeline Kaze | Received |
|
|||
| 11-P08 | A transcriptomic signature of Intrahepatic Cholangiocellular Carcinoma with very early recurrence: Identifying patients at risk | Fabian Haak | Received |
|
|||
| 11-P09 | Atezolizumab/Bevacizumab combination therapy seems to benefit mainly BCLC-C cirrhotic patients with hepatocellular carcinoma who migrate to this stage after disease recurrence following resection or radiofrequency ablation | Spyridon Pantzios | Received |
|
|||
| 11-P04 | Hypofractionated Carbon Ion Radiation in patients with primary liver cancer | Paula Hoffmeister-Wittmann | Received |
|
|||
| 11-P03 | Robotic and laparoscopic surgery versus open surgery for perihilar cholangiocarcinoma: systematic review and meta-analysis | Laynara Vitória Da Silva Vieira | Received |
|
|||
| 12-P07 | Survival in people living with HIV with or without recurrence of hepatocellular carcinoma after invasive therapy | Costanza Bertoni | Received |
|
|||
| 12-P09 | The role of thyroid hormone signalling in liver carcinogenesis: a proof of knowledge | Valentina Cossiga | Received |
|
|||
| 12-P01 | Evaluation of hepatocellular carcinoma and mortality in Budd-Chiari syndrome | Zülal Istemihan | Received |
|
|||
| 12-P02 | Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience. | Margherita Rimini | Received |
|
|||
| 12-P05 | ??????????? ???? ??????????????? ??????????? ????????????????? ????????? | Alexander Fedusenko | Received |
|
|||
| 12-P10 | Expression of MIR-199-5p in chronic viral hepatitis and hepatocellular carcinoma | Elizaveta Joldasova | Received |
|
|||
| 12-P03 | Use of cytokine TGF 1 in DETECTION of Hepatocellular carcinoma in patients with chronic liver disease | Amila Mehmedovic | Received |
|
|||
| 12-P04 | The potential of combined treatments between Src tyrosine kinase inhibitors and sorafenib in heterogeneous liver cancer cells | Loraine Kay Cabral | Received |
|
|||
| 12-P08 | Temporal trends in Hepatocellular carcinoma in Pakistan | Aimun Raees | Received |
|
|||
| 12-P06 | The association of glucagon-like peptide-1 receptor and poor prognosis of Northeastern Thai patients with cholangiocarcinoma | Ronnakrit Trakoonsenathong | Received |
|
|||
| 12-P11 | Reduced expression of YAP is associated with transition of pre-invasive to invasive state in an organoid-derived model of cholangiocarcinoma | Fatima Manzano-Nuñez | Received |
|
|||
| 13-P05 | Inhibiting methionine aminopeptidase 2 suppressed VEGFA-mediated angiogenesis by enhancing phosphorylation of eIF2a | Yongtao Wang | Received |
|
|||
| 13-P08 | The gene expressions and bioinformatics analysis of miR-146b-5p and miR-4510 in Hepatocellular Carcinoma | Duygu BIRCAN KADIOGLU | Received |
|
|||
| 13-P10 | Poor sorafenib response in hepatocellular carcinoma is mediated by hypoxia-related 14-3-3 scaffolding proteins and induces shift in immune micromilieu | Jovana Castven | Received |
|
|||
| 13-P02 | Glycosylated 4-methylumbelliferone reduces the expressions of cancer stem cells in hepatocellular carcinoma | Caecilia Sukowati | Received |
|
|||
| 13-P09 | TARDBP Is a Prognostic Biomarker and Correlates With Immune Infiltrates in Liver hepatocellular carcinoma | Ningning Zhang | Received |
|
|||
| 13-P04 | Investigation of novel hepatoblastoma chemosensitizers based on the inhibition of ABC pumps-mediated drug efflux | Rocio IR Macias | Received |
|
|||
| 13-P06 | Synergistic Anticancer Effect of Immunotherapy and PI3K? Inhibition Combination Therapy in Liver Cancer | Sue Hyuck | Received |
|
|||
| 13-P01 | PRAME is a target of Gas6/Axl signaling in hepatocellular carcinoma | Wolfgang Mikulits | Received |
|
|||
| 13-P07 | It takes a team for HCC: improvement of outcome with the multidisciplinary ambulatory for systemic therapy | Dalbeni Andrea | Received |
|
|||
| 13-P03 | Therapeutic potential of engineered oncolytic virus 3020-VV13 in a pre-clinical model of hepatocellular carcinoma | Hyeree Kim | Received |
|
|||
| 14-P06 | The role of radiomics in the diagnostic and therapeutic path of hepatocellular carcinoma treated with trans arterial radio embolization | Flavia Federici | Received |
|
|||
| 14-P05 | The role of radiomics in diagnosis and therapeutic path of hepatocellular carcinoma treated with transarterial chemoembolization | Paola Ferrari | Received |
|
|||
| 14-P10 | Oncostatin M promotes a pro-tumorigenic inflammatory response in NASH-related HCC | Beatrice Foglia | Received |
|
|||
| 14-P01 | Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab | Bernhard Scheiner | Received |
|
|||
| 14-P09 | Effects of Rifaximin on Epigenetic and Autophagy Markers in an Experimental Model of Hepatocellular Carcinoma Secondary to Non-alcoholic Fatty Liver Disease. | Matheus Michalczuk | Received |
|
|||
| 14-P02 | Cellular interrogation of changes to anti-tumour immunity in Hepatocellular Carcinoma following treatment with combined atezolizumab and bevacizumab using human Precision-Cut Tumour Slices | Ravi Jagatia | Received |
|
|||
| 14-P11 | Carcinogenesis risk factors in cirrhotic patients with dysplastic nodules | Elena Laura Iliescu | Received |
|
|||
| 14-P07 | Hepatocellular Carcinoma cell lines growth inhibition by liver-derived mensenchymal stem cells in direct 3D co-culture | Grégory de Bodt | Received |
|
|||
| 14-P03 | Clinical characteristics, treatments and outcomes in patients diagnosed with hepatocellular carcinoma (HCC) receiving locoregional treatment in England | Sophia Le Mare | Received |
|
|||
| 15-P08 | Tolerance and efficacy of the early switch towards atezolizumab bevacizumab after failure of ive internal radiation therapy for hepatocellular carcinoma | Yasmina Ben Merabet | Received |
|
|||
| 15-P01 | Inhibiting endoplasmic reticulum stress enhances the effect of doxorubicin by affecting lipid metabolism in hepatocellular carcinoma | MARIA KOPSIDA | Received |
|
|||
| 15-P06 | Fascin-1 as a druggable target in agressive hepatoblastoma | Lydia DIF | Received |
|
|||
| 15-P10 | Long-term survival in patients with unresectable liver cancer treated with lenvatinib | Maria Teresa Ferrer Rios | Received |
|
|||
| 15-P02 | Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment different to sorafenib or due to sorafenib intolerance | Marco Sanduzzi Zamparelli | Received |
|
|||
| 15-P05 | Hepatocellular carcinoma incidence and risk stratification in patients with non-alcoholic fatty liver disease on long-term follow-up | Marta Guariglia | Received |
|
|||
| 15-P07 | NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable hepatocellular carcinoma | Domenico Roberti | Received |
|
|||
| 15-P11 | A prospective study for validation of General Evaluation Score for hepatocellular carcinoma risk stratification in chronic hepatitis C patients | Gamal Shiha | Received |
|
|||
| 16-P11 | Influence of the SUSTAINED VIRAL RESPONSE (SVR) in patients with cirrhosis due to HEPATITIS C VIRUS (HCV) and diagnosis of HEPATOCELLULAR CARCINOMA (HCC) | Maria Varela | Received |
|
|||
| 16-P04 | Serum HCC biomarkers AFP, PIVKAII and GPC-3 correlate differently with the HCC characteristics and clinic-pathologic features. | Francesco Damone | Received |
|
|||
| 16-P07 | Establishment and characterization of a patient derived xenograft model of cholangiocarcinoma | Denise Schlösser | Received |
|
|||
| 16-P06 | Glycogen as metabolic fuel for tumor development in glycogen storage disease type III | Valle Montalvo Romeral | Received |
|
|||
| 16-P05 | Prognostic role of thyroid volume reduction in patients treated with lenvatinib for advanced hepatocellular carcinoma | Luca Ielasi | Received |
|
|||
| 16-P08 | INTERLEUKIN-6: a new marker of advanced-sarcopenic HCC cirrhotic patients | Leonardo Antonio Natola | Received |
|
|||
| 16-P01 | Validation of serum biomarker panels for early HCC detection: Results from a large prospective Latin American multicenter study | Boonstra Andre | Received |
|
|||
| 16-P09 | Liposomal doxorubicin targeted with atezolizumab as a novel strategy to cure HCC: preclinical in vitro and in vivo studies | Sara De Martin | Received |
|
|||
| 17-P10 | Peritumoral portal enhancement during transarterial chemoembolization a potential prognostic factor for patients with hepatocellular carcinoma | Sofi Sennefelt Nyman | Received |
|
|||
| 17-P06 | Fatty acid synthase promotes the malignant features of cholangiocarcinoma cells and predicts survival in patients | Giulia Lori | Received |
|
|||
| 17-P05 | Liver function is a predictor of survival in patients with hepatocellular carcinoma in best supportive care | Fabio Marra | Received |
|
|||
| 17-P01 | Poor compliance in the surveillance for Hepatocellular carcinoma (HCC) in a real world setting. | Maria Melanie Deutsch | Received |
|
|||
| 17-P07 | Rising admissions and treatments for hepatocellular carcinoma in Irish hospitals (2009-2020) | William Shanahan | Received |
|
|||
| 17-P03 | Mangiferin & Resveratrol; novel nutraceuticals regulating CD8 cell cytotoxicity and pivotal immunoregulatory pathways in hepatocellular carcinoma | Yousra Eldiwany | Received |
|
|||
| 17-P09 | Insulin-like growth factor-binding proteins 2 and 3 and the occurrence, characteristics, and outcome of hepatitis C-related hepatocellular carcinoma: A case-control study | hend ibrahim shousha | Received |
|
|||
| 17-P04 | Multidisciplinary approach to Hepatocellular Carcinoma management in a low-income country | Aimun Raees | Received |
|
|||
| 17-P08 | Impact of surveillance strategies for hepatocellular carcinoma on patients with chronic liver diseases | Timofte Oana | Received |
|
|||
| 17-P02 | Cystic Fibrosis may be an exclusion criteria for LI-RADS | Chuhadry Khuram Shahzad | Received |
|
|||
| 17-P11 | Inflammation and immune-based prognostic scores as prognostic biomarkers for HCC treatment: A single-center study in the last decade | Merve Guzel Dirim | Received |
|
|||
| 18-P06 | Predictors of extrahepatic recurrence after transarterial chemoembolization as first-line therapy for hepatocellular carcinoma | Elisa Pinto | Received |
|
|||
| 18-P09 | Immune checkpoint inhibitor treatment has the potential to stabilize liver function in patients with hepatocellular carcinoma | Katharina Pomej | Received |
|
|||
| 18-P02 | Influence of hepatocellular carcinoma surveillance programs on cirrhotic patients survival: A real life study | Félix Fernández García | Received |
|
|||
| 18-P03 | Early diagnosis of hepatocellular carcinoma at the level of an infectious diseases hospital | Krestina Brigida | Received |
|
|||
| 18-P04 | Serum protein glycomics in treatment-naive HCC patients are strongly associated to two-year overall survival and HCC relapse | Nicky Somers | Received |
|
|||
| 18-P01 | Prognostic performance of Toronto HCC risk index in patients with Hepatocellular carcinoma | Nouha Trad | Received |
|
|||
| 18-P05 | What changed in hepatocellular carcinoma presentation in the last eleven years? Comparison of two sequential time series from a tertiary hospital | Ana Craciun | Received |
|
|||
| 18-P08 | Immunomonitoring of hepatocellular carcinoma patients undergoing liver transplantation after treatment with Bevacizumab and Atezolizumab | Sherrie Bhoori | Received |
|
|||
| 18-P07 | Programmable DNA hydrogel assisting microcrystal formulations for sustained locoregional drug delivery in residual tumor foci | Hao Feng | Received |
|
|||
| 18-P10 | Gender differences in patients with hepatocellular carcinoma | Agata Ladic | Received |
|
|||
| 19-P07 | Varices and thrombocytopenia are predictors of survival outcome after liver resection for hepatocellular carcinoma (HCC): a twenty-year retrospective study | Samir Tariq | Received |
|
|||
| 19-P01 | Ablation of large HCC using a new mini-invasive RFA device with 4 very thincool-tip needles | Luciano Tarantino | Received |
|
|||
| 19-P04 | Efficacy of LENVATINIB in intermediate stage and advanced HEPATOCELLULAR CARCINOMA: results of MONOTHERAPY and COMBINATION with LOCOREGIONAL TREATMENT | Margherita Spigaroli | Received |
|
|||
| 19-P09 | Comparison between hepatocellular carcinoma in alcohol related disease versus other etiologies - are they the same or not quite yet? A retrospective analysis. | Jessica Chaves | Received |
|
|||
| 19-P08 | Fib4 can help cost effective HCC screening populations in Child Pugh A cirrhosis | Paul Armstrong | Received |
|
|||
| 19-P03 | In vivo characterization of the impact of distinct p53 mutations in hepatocellular carcinoma | Marine Bernardet | Received |
|
|||
| 19-P02 | Liver transplantation for HCC beyond Milan criteria after down-staging with stereotactic radiotherapy or transarterial radioembolization | Alberto Calleri | Received |
|
|||
| 19-P11 | Epidemiology of hepatocelullar carcinoma in transylvania | Elena Cristina Rezi | Received |
|
|||
| 20-P05 | Disparities in access to timely diagnosis and treatment for hepatocellular carcinoma - need for standardisation across cancer types | Niamh Mehigan | Received |
|
|||
| 20-P10 | Assesment Of GALAD Score As Diagnostic And Prognostic Factor Of Denovo Hepatocellular Carcinoma Post Treatment With Direct Acting Antiviral Agents | hend ibrahim shousha | Received |
|
|||
| 20-P08 | TKI treatments for HCC before liver transplantation: a collaborative European study. | Chiara Mazzarelli | Received |
|
|||
| 20-P09 | PNPLA3 rs738409 CG polymorphism impact on HCV-Related HCC development in a Brazilian population: preliminary results | Claudia Maccali | Received |
|
|||
| 20-P04 | Is ALBI score alone a good predictor for outcome in patients treated with radioembolization for hepatocellular carcinoma? | maria alessia papassifachis | Received |
|
|||
| 21-P3 | Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network | Yongkun Ji | Received |
|
|||
Liver Cancer Summit 2023
20-22 April, Estoril
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 20/04/2023 TO 20/04/2024
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
Poster submission deadline 20/04/2023
|
|
